Published in Semin Thromb Hemost on January 01, 2000
Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol (2011) 2.14
Extracellular matrix and matrix receptors in blood-brain barrier formation and stroke. Dev Neurobiol (2011) 1.18
A fibrinogen-based precision microporous scaffold for tissue engineering. Biomaterials (2007) 1.12
Effect of fibrin glue on the biomechanical properties of human Descemet's membrane. PLoS One (2012) 0.89
Autotransfusion management during and after cardiopulmonary bypass alters fibrin degradation and transfusion requirements. J Extra Corpor Technol (2007) 0.87
Inducing chemotactic and haptotactic cues in microfluidic devices for three-dimensional in vitro assays. Biomicrofluidics (2014) 0.83
Fibrin gel as an injectable biodegradable scaffold and cell carrier for tissue engineering. ScientificWorldJournal (2015) 0.81
The membrane attack complex of complement contributes to plasmin-induced synthesis of platelet-activating factor by endothelial cells and neutrophils. Immunology (2003) 0.80
Reactive carbonyl compounds (RCCs) cause aggregation and dysfunction of fibrinogen. Protein Cell (2012) 0.80
Optimization of Three Dimensional Culturing of the HepG2 Cell Line in Fibrin Scaffold. Hepat Mon (2015) 0.78
A quantitative trait locus on chromosome 5p influences d-dimer levels in the san antonio family heart study. Int J Vasc Med (2010) 0.76
Protein/Peptide Aggregation and Amyloidosis on Biointerfaces. Materials (Basel) (2016) 0.75
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Plasminogen activator inhibitors. Blood (1987) 2.38
A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemost (1982) 2.22
Guidelines on preparation, certification, and use of certified plasmas for ISI calibration and INR determination. J Thromb Haemost (2004) 2.21
Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet (2001) 2.15
Effect on blood lipids, coagulation, and fibrinolysis of a fat high in myristic acid and a fat high in palmitic acid. Am J Clin Nutr (1994) 2.12
Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med (1998) 1.97
Vitamin D status and its adequacy in healthy Danish perimenopausal women: relationships to dietary intake, sun exposure and serum parathyroid hormone. Br J Nutr (2001) 1.84
Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation (1996) 1.80
Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost (1984) 1.72
An extensive analysis of Y-chromosomal microsatellite haplotypes in globally dispersed human populations. Am J Hum Genet (2001) 1.70
Effect of moderate dose of alcohol with evening meal on fibrinolytic factors. BMJ (1994) 1.65
Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med (1996) 1.48
Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric (2011) 1.47
Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. Lancet (1998) 1.47
Tissue plasminogen activator inhibition in diabetes mellitus. Diabetes Care (1989) 1.45
A comparison of artificially-depleted, lyophilized coumarin and fresh coumarin plasmas in thromboplastin calibration. European Concerted Action on Anticoagulation. Br J Haematol (1998) 1.44
Effects of moderate alcohol consumption on platelet aggregation, fibrinolysis, and blood lipids. Metabolism (1987) 1.44
Modulation of plasma fibrinogen levels by ticlopidine in healthy volunteers and patients with stable angina pectoris. Thromb Haemost (1996) 1.40
A simplified statistical method for local INR using linear regression. European Concerted Action on Anticoagulation. Br J Haematol (1997) 1.40
Long-lasting depression of the factor XII-dependent fibrinolytic system in patients with myocardial infarction undergoing thrombolytic therapy with recombinant tissue-type plasminogen activator: a randomized placebo-controlled study. J Am Coll Cardiol (1991) 1.39
Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol (1988) 1.31
Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years. Clin Endocrinol (Oxf) (2004) 1.30
Moderate alcohol consumption reduces plasma C-reactive protein and fibrinogen levels; a randomized, diet-controlled intervention study. Eur J Clin Nutr (2002) 1.27
Soluble intercellular adhesion molecule 1 and flow-mediated dilatation are related to the estimated risk of coronary heart disease independently from each other. Atherosclerosis (2003) 1.23
The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest (1985) 1.22
Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl Psychiatry (2012) 1.22
Are olive oil diets antithrombotic? Diets enriched with olive, rapeseed, or sunflower oil affect postprandial factor VII differently. Am J Clin Nutr (1999) 1.18
Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. Arterioscler Thromb Vasc Biol (1996) 1.15
Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arterioscler Thromb (1993) 1.14
Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim Biophys Acta (1993) 1.14
Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin. Eur J Biochem (1986) 1.14
Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives: a rebuttal. J Thromb Haemost (2013) 1.12
Localization of a gene for autosomal dominant osteopetrosis (Albers-Schönberg disease) to chromosome 1p21. Am J Hum Genet (1997) 1.11
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a rebuttal. J Thromb Haemost (2013) 1.10
Determinants of C-reactive protein concentration in blood. Ital Heart J (2001) 1.10
Circadian variation of fibrinolytic activity in blood. Chronobiol Int (1991) 1.10
Assignment of the human gene for histidine-rich glycoprotein to chromosome 3. Genomics (1990) 1.08
Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis (2003) 1.07
Protein C activation during the initial phase of experimental acute pancreatitis in the rabbit. Dig Surg (1999) 1.06
A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasmin. Blood (1982) 1.04
Genetic influence on thrombotic risk markers in the elderly--a Danish twin study. J Thromb Haemost (2005) 1.02
Determination of prekallikrein in human plasma: optimal conditions for activating prekallikrein. J Lab Clin Med (1978) 1.02
Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation (1994) 1.02
The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism (1993) 1.02
Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: a randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study. J Bone Miner Res (2003) 1.02
Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis (1996) 1.01
Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia (1997) 1.00
An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. J Thromb Haemost (2008) 1.00
Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study. Maturitas (2000) 1.00
Factual or artificial inhibition of fibrinolysis and the occurrence of venous thrombosis in 3 cases of Behçet's disease. Scand J Haematol (1980) 0.99
Specificity of antigen assays of plasminogen activator inhibitor in plasma: Innotest PAI-1 immunoassay evaluated. Clin Chem (1994) 0.97
European Concerted Action on Anticoagulation (ECAA)-the multicentre calibration of rabbit and human ECAA reference thromboplastins. Steering Committee. Thromb Haemost (1996) 0.96
Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. Thromb Res (1996) 0.96
Minimum lyophilized plasma requirement for ISI calibration. European Concerted Action on Anticoagulation. Am J Clin Pathol (1998) 0.95
Occurrence of C1 inactivator and other proteinase inhibitors in euglobulin fractions and their influence on fibrinolytic activity. Haemostasis (1976) 0.95
The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers--two independent studies. J Thromb Haemost (2011) 0.94
The preparation of tissue-type Plasminogen Activator (t-PA) containing liposomes: entrapment efficiency and ultracentrifugation damage. J Drug Target (1995) 0.94
Role of the contact system in fibrinolysis. Semin Thromb Hemost (1987) 0.94
A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology (1991) 0.93
European Concerted Action on Anticoagulation (ECAA): multicentre international sensitivity index calibration of two types of point-of-care prothrombin time monitor systems. Br J Haematol (2002) 0.93
Elevated plasma fibrinogen: cause or consequence of cardiovascular disease? Arterioscler Thromb Vasc Biol (1998) 0.93
Intake of n-3 fatty acids from fish does not lower serum concentrations of C-reactive protein in healthy subjects. Eur J Clin Nutr (2004) 0.93
Effects of total fat content and fatty acid composition in diet on factor VII coagulant activity and blood lipids. Atherosclerosis (1990) 0.92
Demonstration of urokinase-related fibrinolytic activity in human plasma. Br J Haematol (1982) 0.92
The effect of low-dose acetylsalicylic acid on bleeding after transurethral prostatectomy--a prospective, randomized, double-blind, placebo-controlled study. Scand J Urol Nephrol (2000) 0.92
European Concerted Action on Anticoagulation (ECAA). An assessment of lyophilised plasmas for ISI calibration of CoaguChek and TAS whole blood prothrombin time monitors. J Clin Pathol (2003) 0.92
Homozygous alpha 2-antiplasmin deficiency. Lancet (1979) 0.92
The variability of and associations between measures of blood coagulation, fibrinolysis and blood lipids. Atherosclerosis (1992) 0.92
Quantification of tissue-type plasminogen activator (t-PA) mRNA in human endothelial-cell cultures by hybridization with a t-PA cDNA probe. Biochem J (1986) 0.92
Fat high in stearic acid favorably affects blood lipids and factor VII coagulant activity in comparison with fats high in palmitic acid or high in myristic and lauric acids. Am J Clin Nutr (1994) 0.92
Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol (1999) 0.92
Longevity is independent of common variations in genes associated with cardiovascular risk. Thromb Haemost (1999) 0.91
Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest (1995) 0.91
Episodic activation of the coagulation system in unstable angina does not elicit an acute phase reaction. Am J Cardiol (1996) 0.91
Logistics and quality control for DNA sampling in large multicenter studies. J Thromb Haemost (2003) 0.91
Cytokines and bone loss in a 5-year longitudinal study--hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: the Danish Osteoporosis Prevention Study. J Bone Miner Res (2000) 0.91
Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. Arzneimittelforschung (1988) 0.91
CD4 T lymphocytes from patients with chronic fatigue syndrome have decreased interferon-gamma production and increased sensitivity to dexamethasone. J Infect Dis (1998) 0.91
European Concerted Action on Anticoagulation--comparison of fresh plasma and whole blood multicentre ISI calibrations of CoaguChek Mini and TAS PT-NC whole blood prothrombin time point-of-care monitors. Thromb Haemost (2002) 0.90
Identification of a reversible inhibitor of plasminogen activators in blood plasma. FEBS Lett (1985) 0.90
The effect of sample size on fresh plasma thromboplastin ISI determination. Br J Haematol (1999) 0.90
The influence of L-asparaginase therapy on the fibrinolytic system. Br J Haematol (1984) 0.90
Evaluation of methods for prediction of bone mineral density by clinical and biochemical variables in perimenopausal women. Maturitas (2001) 0.90
The harmonization of quantitative test results of different D-dimer methods. Semin Vasc Med (2005) 0.89
Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study. Circulation (1997) 0.89
Inflammation, thrombosis and atherosclerosis: results of the Glostrup study. J Thromb Haemost (2003) 0.89
Fibrinogen Milano II: a congenital dysfibrinogenaemia associated with juvenile arterial and venous thrombosis. Thromb Haemost (1986) 0.89
Blood sample stability at room temperature for counting red and white blood cells and platelets. Vascul Pharmacol (2002) 0.89
Mapping of autosomal dominant osteopetrosis type II (Albers-Schönberg disease) to chromosome 16p13.3. Am J Hum Genet (2001) 0.89
Effect of fish diet versus meat diet on blood lipids, coagulation and fibrinolysis in healthy young men. J Intern Med (1991) 0.88